Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.05 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.32 +12.1% TUNG 1.73 +2.4% LGO 1.00 −3.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.50 +1.1% SGZ 0.040 −11.1% GRSL 0.307 −3.9% DEX 0.380 −1.3% WMS 0.040 +0.0% S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.05 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.32 +12.1% TUNG 1.73 +2.4% LGO 1.00 −3.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.50 +1.1% SGZ 0.040 −11.1% GRSL 0.307 −3.9% DEX 0.380 −1.3% WMS 0.040 +0.0%
M&A / Property

Therma Bright wins order for 100 Venowave units

By The Northwire Desk — AI Analysis Mar 31, 2026 · 15:32 THRM · 0.065 Therma Bright Inc
THRM · Price

Executive Summary

  • Therma Bright Inc. has secured a strategic commercial order for an initial 100 Venowave units from Horizon Health, a major durable medical equipment (DME) leader.
  • This order follows a successful 2025 proof-of-concept phase, during which Therma Bright optimized its delivery and support protocols for the U.S. market.
  • Horizon Health currently prescribes over 3,000 compression products per month and maintains deep clinical ties with prestigious institutions, including MedStar Health and the University of Maryland.

Key Details

  • Transaction: Initial order for 100 Venowave units.
  • Counterparty: Horizon Health (headquartered in Baltimore, Md.).
  • Counterparty Scale: Horizon Health manages a network that prescribes over 3,000 compression products per month and sells over 35,000 compression products annually.
  • Strategic Context: The order validates the 2025 proof-of-concept phase and positions Therma Bright to capture share in the high-volume vascular recovery market in the Mid-Atlantic region and nationally.
  • New Market Expansion: Therma Bright is actively investigating opportunities to position Venowave for cosmetic applications within wellness and aesthetic health care clinics across the U.S., specifically for lymphatic drainage and post-procedure recovery.
  • Clinical Partnerships: Horizon Health has ties to MedStar Health, the University of Maryland, and over 50 specialized surgical centres.

Notable Quotes

  • Rob Fia, CEO of Therma Bright: "Securing this 100-unit order from Horizon Health is a pivotal moment for our commercial scaling strategy... Their extensive reach into surgical centres and top-tier hospitals provides the perfect launch pad for Venowave to become a standard of care in mobile compression."
  • James Stadler, Co-CEO of Horizon Health: "Our doctors and patients demand the most effective, mobile and patient-compliant solutions for vascular health... we are excited to partner with Therma Bright to integrate this unique technology into our national distribution network."
  • Steve Ebner, Co-CEO of Horizon Health: "The continuum of care for patients following a major procedure is paramount... The Venowave enhances clinical outcomes by supporting patients where they are most at risk: at home."
Read the original news release →

More from Therma Bright Inc

Jun 23, 2026 · 06:31

Therma Bright Announces Expanded U.S. Orders for Venowave and Mobilizes Supply Chain for Upcoming Sales Volume

Financings May 05, 2026 · 06:31

Therma Bright Secures Repeat Orders, But Scale Remains Questionable Amidst Capital Needs

Production / Operations Mar 31, 2026 · 06:31

[Value]

Other Feb 10, 2026 · 17:09

Therma portfolio co. completes FIH stroke cohort

Regulatory Feb 10, 2026 · 07:01

Therma Bright Portfolio Update: Inretio Successfully Completes First-in-Human Cohort for PREVA(TM) Stroke Platform; Targets 2026 U.S. FDA Trial

Regulatory Jan 20, 2026 · 15:40

Therma Bright receives order for 200 Venowave VW5 units

Other